Nanoemulsion Vaccine Compositions for Th2 Allergy Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional treatments for allergic and inflammatory diseases, such as steroids and oral immunotherapy, have significant drawbacks including undesirable side effects and limited effectiveness in inducing long-term tolerance, while existing vaccines do not adequately address the underlying immunological bases of these conditions.
Innovation Solution
Nanoemulsion-based vaccines are administered to stimulate immune responses, reducing allergic reactions by modulating Th2-type cytokines and promoting Th1-type responses, thereby treating or preventing allergic and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional treatments such as steroids are used to treat allergic diseases, then allergic symptoms are suppressed, but undesirable side effects occur and the underlying immunological basis is not addressed
Solution Approach 1:
The patent converts the harmful Th2-type immune response that causes allergies into a beneficial therapeutic outcome by using nanoemulsion vaccines to induce Th1-type responses. The harmful allergic reactions are transformed into controlled immune modulation, where the immune system is redirected to produce protective Th1 responses that suppress the pathological Th2 responses, thereby eliminating side effects while treating the underlying immunological basis.
Solution Approach 2:
The patent changes the immunological parameters by shifting the immune response balance from Th2-dominant (allergic) to Th1-dominant (protective). This is achieved through nanoemulsion-based vaccines that modify cytokine profiles, reducing Th2 cytokines (IL-4, IL-5, IL-13) and increasing Th1 cytokines (IFN-gamma, TNF-alpha, IL-17), thereby fundamentally altering the immune response characteristics to eliminate both symptoms and side effects.
2Object-affected harmful factors
If oral immunotherapy is used to desensitize patients to food antigens, then some individuals show reduced allergic reactions, but the procedure requires frequent and prolonged intake and carries significant risk for severe adverse reactions
Solution Approach 1:
The patent introduces nanoemulsion-based vaccines as an intermediary therapeutic agent that mediates immune modulation without requiring direct exposure to offending food antigens. Unlike oral immunotherapy that requires frequent ingestion of allergens, the nanoemulsion vaccine delivers immunomodulatory components that safely redirect the immune response, eliminating the need for prolonged allergen exposure and reducing the risk of severe adverse reactions while achieving desensitization.
Solution Approach 2:
The patent applies preliminary immune modulation through nanoemulsion vaccination before challenging the patient with allergens. By pre-establishing Th1-type immune responses and reducing Th2 dominance through the nanoemulsion vaccine, the patient's immune system is prepared to tolerate allergens more safely, reducing the need for frequent prolonged exposure and minimizing the risk of severe reactions during desensitization.
3Reliability
If existing vaccines are used to treat allergic diseases, then some immune response is stimulated, but they do not adequately address the underlying Th2-type immunological basis
Solution Approach 1:
The patent applies local quality by specifically targeting Th2-type cytokine pathways with nanoemulsion-based vaccines designed to modulate particular immune responses. Unlike conventional vaccines that provide general immune stimulation, the nanoemulsion vaccine is specifically formulated to reduce Th2 cytokines (IL-4, IL-5, IL-13) while promoting Th1 responses, providing targeted immunological correction that addresses the specific Th2-type immunological basis of allergies while maintaining reliable immune response stimulation.
Data Source
AI summary
The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.